Matinas Biopharma Holdings, Inc. (MTNB) News
Filter MTNB News Items
MTNB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MTNB News Highlights
- MTNB's 30 day story count now stands at 2.
- Over the past 6 days, the trend for MTNB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MTNB are DEC, MRNA and LNC.
Latest MTNB News From Around the Web
Below are the latest news stories about MATINAS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate MTNB as an investment opportunity.
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesIn an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions BEDMINSTER, N.J, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbr |
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAWritten Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design Partnership Discussions Remain Ongoing for MAT2203 BEDMINSTER, N.J., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) pl |
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript November 8, 2023 Matinas BioPharma Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, […] |
12 Best Day Trading Stocks To BuyIn this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, […] |
Q3 2023 Matinas BioPharma Holdings Inc Earnings CallQ3 2023 Matinas BioPharma Holdings Inc Earnings Call |
Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business ProgressKey Developments and Financial Highlights for Investors |
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateFDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to strengthen commercial opportunity without increasing study size Patient with Candida krusei infection achieved complete clinical resolution with MAT2203; additional patient enrolled in the Compassionate/Expanded Use Access Program Oral LNC formulation of docetaxel showed reductio |
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelStudy results show reduction in tumor size comparable to IV docetaxel and no systemic toxicityBEDMINSTER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the manageme |
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023BEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report third quarter 2023 financial results after market close on Wednesday, November 8, 2023. Matinas management will host an investment community conference call and webcast to discuss |
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionBEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei (C. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifung |